Another Denosumab Deal For mAbxience In MEA
MS Pharma Is Set To Register And Market The Prolia/Xgeva Biosimilar In MEA Markets
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
